Actuate Therapeutics to be Added to Russell 2000® Index
Actuate Therapeutics (NASDAQ: ACTU), a clinical-stage biopharmaceutical company developing therapies for difficult-to-treat cancers, announced its upcoming addition to the Russell 2000® Index. The inclusion will be effective after U.S. market opens on December 23, 2024, as part of the fourth quarter IPO additions. The Russell 2000® Index, representing approximately 10% of the Russell 3000® Index's total market capitalization, measures the performance of the U.S. equity market's small-cap segment and includes about 2,000 of the smallest securities.
Actuate Therapeutics (NASDAQ: ACTU), un'azienda biofarmaceutica in fase clinica che sviluppa terapie per tumori difficili da trattare, ha annunciato la sua prossima inclusione nell'Indice Russell 2000®. L'inclusione sarà effettiva dopo l'apertura del mercato statunitense il 23 dicembre 2024, come parte delle aggiunte IPO del quarto trimestre. L'Indice Russell 2000®, che rappresenta circa il 10% della capitalizzazione di mercato totale dell'Indice Russell 3000®, misura le performance del segmento delle piccole capitalizzazioni del mercato azionario statunitense e include circa 2.000 delle più piccole società.
Actuate Therapeutics (NASDAQ: ACTU), una empresa biofarmacéutica en etapa clínica que desarrolla terapias para cánceres difíciles de tratar, anunció su próxima inclusión en el Índice Russell 2000®. La inclusión será efectiva después de la apertura del mercado estadounidense el 23 de diciembre de 2024, como parte de las adiciones de IPO del cuarto trimestre. El Índice Russell 2000®, que representa aproximadamente el 10% de la capitalización de mercado total del Índice Russell 3000®, mide el rendimiento del segmento de pequeñas capitalizaciones del mercado de valores de EE. UU. e incluye alrededor de 2,000 de los valores más pequeños.
Actuate Therapeutics (NASDAQ: ACTU)는 치료하기 어려운 암에 대한 치료법을 개발하는 임상 단계의 생명공학 회사로, 러셀 2000® 지수에 추가될 예정이라고 발표했습니다. 이 포함은 2024년 12월 23일 미국 시장 개장 이후에 시행될 예정이며, 이는 4분기 IPO 추가의 일환입니다. 러셀 2000® 지수는 러셀 3000® 지수의 총 시가총액의 약 10%를 차지하며, 미국 주식 시장의 소형주 부문의 성과를 측정하고 약 2,000개의 가장 작은 증권을 포함합니다.
Actuate Therapeutics (NASDAQ: ACTU), une entreprise biopharmaceutique en phase clinique développant des thérapies pour des cancers difficiles à traiter, a annoncé son imminente inclusion dans le Russell 2000® Index. L'inclusion sera effective après l'ouverture du marché américain le 23 décembre 2024, dans le cadre des ajouts IPO du quatrième trimestre. L'Indice Russell 2000®, représentant environ 10 % de la capitalisation boursière totale de l'Indice Russell 3000®, mesure la performance du segment des petites capitalisations du marché boursier américain et comprend environ 2 000 des plus petites valeurs.
Actuate Therapeutics (NASDAQ: ACTU), ein biopharmazeutisches Unternehmen in klinischer Phase, das Therapien für schwer behandelbare Krebserkrankungen entwickelt, hat seine bevorstehende Aufnahme in den Russell 2000® Index bekannt gegeben. Die Aufnahme wird nach Eröffnung des US-Marktes am 23. Dezember 2024 wirksam, im Rahmen der IPO-Zugänge des vierten Quartals. Der Russell 2000® Index, der etwa 10% der Gesamtmarktkapitalisierung des Russell 3000® Index ausmacht, misst die Performance des Segments der Kleinunternehmen des US-Aktienmarktes und umfasst etwa 2.000 der kleinsten Wertpapiere.
- Addition to Russell 2000® Index, potentially increasing stock visibility and trading volume
- Inclusion could attract more institutional investors and index funds
- None.
Insights
The addition to the Russell 2000® Index represents a significant milestone for Actuate Therapeutics, as it will increase the company's visibility among institutional investors and index funds that track this benchmark. Index inclusion typically leads to increased trading volume and liquidity, as passive funds that track the Russell 2000® will need to purchase ACTU shares. With a market cap of
However, investors should note that index inclusion alone doesn't change the company's fundamental value or clinical development progress. The increased liquidity could lead to higher short-term price volatility as institutional investors adjust their positions.
CHICAGO and FORT WORTH, Texas, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers announced today that the Company will be added to the Russell 2000® Index as part of the planned fourth quarter IPO additions effective after the U.S market opens on December 23, 2024.
The Russell 2000® Index measures the performance of the small-cap segment of the US equity market. The Russell 2000® Index is a subset of the Russell 3000® Index representing approximately
About Actuate Therapeutics, Inc.
Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate’s lead investigational drug product, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy including several DDR pathways. Elraglusib is designed to act as a mediator of anti-tumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function. For additional information, please visit the Company’s website at http://www.actuatetherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements about us, including our clinical trials, development plans, industry, and our planned addition of the Russell 2000® Index. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All statements, other than statements related to present facts or current conditions or of historical facts, contained in this press release are forward-looking statements. Accordingly, these statements involve estimates, assumptions, substantial risks and uncertainties which could cause actual results to differ materially from those expressed in them, including but not limited to the potential benefits of and continued inclusion of the Company in the Russell 2000® Index, that clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes, results of prior preclinical studies and early clinical trials are not necessarily predictive of future results, and elraglusib may not achieve favorable results in clinical trials or preclinical studies or receive regulatory approval on a timely basis, if at all; that we may not successfully enroll additional patients or establish or advance plans for further development; that elraglusib could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude regulatory approval, cause us to suspend or discontinue clinical trials or result in other negative consequences; our reliance on third parties to conduct our non-clinical studies and our clinical trials; our reliance on third-party licensors and ability to preserve and protect our intellectual property rights; that we face significant competition from other biotechnology and pharmaceutical companies; and our ability to fund development activities. In addition, any forward-looking statements are qualified in their entirety by reference to the factors discussed under the heading “Item 1A. Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 filed with the SEC on November 13, 2024 and other filings with the SEC. Because the risk factors referred to above could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Unless legally required, we do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
Investor Contact
Mike Moyer
Managing Director
LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
FAQ
When will Actuate Therapeutics (ACTU) be added to the Russell 2000 Index?
Why is Actuate Therapeutics (ACTU) being added to the Russell 2000 Index?
What percentage of the Russell 3000 Index does the Russell 2000 represent for ACTU?
